Abstract

Transition metal-based compounds have shown promising uses as therapeutic agents. Among their unique characteristics, these compounds are suitable for interaction with specific biological targets, making them important potential drugs to treat various diseases. Copper compounds, of which Casiopeinas® are an excellent example, have shown promising results as alternatives to current cancer therapies, in part because of their intercalative properties with DNA. Vanadium compounds have been extensively studied for their pharmacological properties and application, mostly in diabetes, although recently, there is a growing interest in testing their activity as anti-cancer agents. In the present work, two compounds, [Cu(Metf)(bipy)Cl]Cl·2H2O and [Cu(Impy)(Gly)(H2O)]VO3, were obtained and characterized by visible and FTIR spectroscopies, single-crystal X-ray diffraction, and theoretical methods. The structural and electronic properties of the compounds were calculated through the density functional theory (DFT) using the Austin–Frisch–Petersson functional with dispersion APFD, and the 6-311 + G(2d,p) basis set. Non-covalent interactions were analyzed using Hirshfeld surface analysis (HSA) and atom in molecules analysis (AIM). Additionally, docking analysis to test DNA/RNA interactions with the Casiopeina-like complexes were carried out. The compounds provide metals that can interact with critical biological targets. In addition, they show interesting non-covalent interactions that are responsible for their supramolecular arrangements.

Highlights

  • Cancer represents a significant public health problem worldwide

  • We report the synthesis and experimental–theoretical characterization of two new compounds resulting from our search to complete the cyclotetravanadate copper complexes family

  • Copper complexes are among the most studied transition metal complexes for their antitumor properties because endogenous metal ions may lead to less systemic toxicity

Read more

Summary

Introduction

18.1 million new cancer cases and 9.6 million cancer deaths worldwide in 2018, it is relevant to find low-cost and safe alternatives to combat it [1]. As the second leading cause of death in the Americas, cancer caused 1.3 million deaths in 2018, and 3.7 million new cases were reported. 2020, 25, 4679 clinical useMolecules of platinum-based drugs entails many severe side effects, such as nephrotoxicity [8], neurotoxicity [9], and ototoxicity and myelosuppression [10]. It is assumed that antitumor drugs of cancer cases metals is estimated to increase by 32%, million newthan cases platinum due to the aging of the [11].

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call